Latest News-Insilico Medicine Mediaroom_Page

Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE

* For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclini...

2026-04-24 21:00 4163

Nature Reviews Drug Discovery | Target Identification and Assessment in the Era of AI

CAMBRIDGE, Mass., April 22, 2026 /PRNewswire/ -- Target identification is the first and perhaps mos...

2026-04-22 21:00 4918

Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery

CAMBRIDGE, Mass., April 21, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinica...

2026-04-21 21:05 6000

Insilico Medicine Announces Global R&D Collaboration with Lilly

AI-driven collaboration includes an exclusive worldwide license for a portfolio of programs spannin...

2026-03-30 08:30 6376

Insilico Medicine and Tenacia Biotechnology Expand AI-Driven CNS Collaboration with Deal Value Up to US$94.75 Million

CAMBRIDGE, Mass., March 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinica...

2026-03-26 22:08 6921

Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women's Health

CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug...

2026-03-24 18:29 4339

Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery

CAMBRIDGE, Mass., March 23, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage g...

2026-03-23 20:30 5704

Insilico Medicine to Announce 2025 Financial Results on March 30, 2026

CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696.HK, "Insilico" or th...

2026-03-13 21:59 9904

Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial

CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Insilico Medicine (Insilico Medicine, HKEX: 03696),...

2026-03-06 18:53 6974

Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery

Single 2.6B-parameter model achieves state-of-the-art performance across drug discovery benchmarks ...

2026-03-03 22:25 6844

Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery

AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases

CAMBRIDGE, Mass., Feb. 10, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinica...

2026-02-10 21:00 8400

Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology

CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinic...

2026-02-06 21:00 9242

Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications

* NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cyto...

2026-02-05 21:00 8538

Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501

Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilic...

2026-02-03 22:00 8286

Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies

CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology c...

2026-01-27 22:00 9498

Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor

* Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves ...

2026-01-23 21:30 15254

Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines

* New "AI GYM for Science" dramatically boosts the biological and chemical intelligence of any ca...

2026-01-22 22:37 10537

Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment

* Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health...

2026-01-21 08:15 8451

Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease

CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage, g...

2026-01-12 21:30 8592

Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology

* Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, fo...

2026-01-05 08:30 8958